Mitochondrial ncRNAs: From Pathological Regulation to Targeted Therapy in Cardiovascular Diseases.
C, L. & Q, Y. (2026). Mitochondrial ncRNAs: From Pathological Regulation to Targeted Therapy in Cardiovascular Diseases.. Journal of cardiovascular translational research. https://doi.org/10.1007/s12265-026-10809-0
C L, Q Y. Mitochondrial ncRNAs: From Pathological Regulation to Targeted Therapy in Cardiovascular Diseases.. Journal of cardiovascular translational research. 2026; doi: 10.1007/s12265-026-10809-0
C L, Q Y. Mitochondrial ncRNAs: From Pathological Regulation to Targeted Therapy in Cardiovascular Diseases.[J]. Journal of cardiovascular translational research. 2026. DOI: 10.1007/s12265-026-10809-0.
@article{c2026,
author = {Li C and Yuan Q},
title = {Mitochondrial ncRNAs: From Pathological Regulation to Targeted Therapy in Cardiovascular Diseases.},
journal = {Journal of cardiovascular translational research},
year = {2026},
doi = {10.1007/s12265-026-10809-0},
note = {PMID: 42440158},
}
TY - JOUR AU - Li C AU - Yuan Q TI - Mitochondrial ncRNAs: From Pathological Regulation to Targeted Therapy in Cardiovascular Diseases. T2 - Journal of cardiovascular translational research PY - 2026 DO - 10.1007/s12265-026-10809-0 AN - PMID:42440158 ER -
Heart failure (HF) is closely linked to mitochondrial dysfunction, featured by abnormal energy metabolism, excessive reactive oxygen species (ROS), and imbalanced mitochondrial dynamics. Clinically, effective targeted therapies for mitochondrial dysfunction are still lacking, which aggravates HF and multi-organ injury. Mitochondrial non-coding RNAs (mt-ncRNAs) form a regulatory network critical for mitochondrial function. Among them, mitochondrial-encoded circular RNAs (mecciRNAs) and mitochondrial double-stranded RNAs (mt-dsRNAs) are research hotspots. mecciRNAs protect the heart by assisting protein import and regulating mitochondrial pores and ROS; their degradation worsens HF, while exogenous supplementation alleviates injury. mt-dsRNAs arise from aberrant mitochondrial transcription and contribute to myocardial injury and remodeling via MAVS, cGAS-STING, and PNPT1 pathways. Gene therapy targeting mecciRNAs and mt-dsRNAs combined with mitochondrial delivery represents a promising strategy for HF treatment.